• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    electroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/7/25 4:25:21 PM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ECOR alert in real time by email
    false 0001560258 0001560258 2025-05-07 2025-05-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported)

    May 7, 2025

     

    electroCore, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38538   20-3454976

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification Number)

     

    200 Forge Way, Suite 205

    Rockaway, NJ 07866

    (Address of principal executive offices and zip code)

     

    (973) 290-0097

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class  

    Trading symbol(s)

     

    Name of each exchange on which registered

    Common Stock, Par Value $0.001 Per Share   ECOR   NASDAQ Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition.

     

    On May 7, 2025, electroCore, Inc. (the “Company”) issued a press release (i) announcing its financial results for the quarter ended March 31, 2025, and (ii) providing preliminary guidance for the full 2025 fiscal year. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference.

     

    Except for information relating to Adjusted EBITDA net loss from operations and its reconciliation to generally accepted accounting principles (GAAP), the information contained in this Item 2.02 and Item 9.01 in this Current Report on Form 8-K, including the accompanying Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.

     

    Description of Exhibit

    99.1   Press release dated May 7, 2025.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      electroCore, Inc.
       
    May 7, 2025 /s/ Joshua S. Lev
      Joshua S. Lev
      Chief Financial Officer

     

     

     

     

     

     

     

    Get the next $ECOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ECOR

    DatePrice TargetRatingAnalyst
    1/19/2022$3.00 → $2.75Buy
    HC Wainwright & Co.
    7/27/2021$3.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $ECOR
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by electroCore Inc.

      SCHEDULE 13D - electroCore, Inc. (0001560258) (Subject)

      5/14/25 9:02:34 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by electroCore Inc.

      10-Q - electroCore, Inc. (0001560258) (Filer)

      5/7/25 4:30:50 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • electroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - electroCore, Inc. (0001560258) (Filer)

      5/7/25 4:25:21 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • electroCore Announces First Quarter 2025 Financial Results

      First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. ("NeuroMetrix"); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights Reported first quarter 2025 revenue of $6.7 million, a 23% increase over first quarter 2024Revenue excluding TAC-STIM totaled $

      5/7/25 4:05:00 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • electroCore Completes Acquisition of NeuroMetrix, Gaining Access to its Quell Platform, Creating Significant Player in Non-Invasive Bioelectronic Technologies

      ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. ("ECOR," "electroCore," or the "Company") (NASDAQ:ECOR), a commercial-stage bioelectronic technology company, announced today the completion of the merger (the "Merger") with NeuroMetrix, Inc. ("NeuroMetrix" or "NURO") (NASDAQ:NURO), positioning itself as a diversified leader in non-invasive health and wellness solutions. The acquisition of NeuroMetrix's Quell® Fibromyalgia Solution expands electroCore's portfolio of non-invasive bioelectronic therapies, strengthens its commercial reach — particularly within the VA Hospital System — and is expected to meaningfully increase its addressable market for the treatment of chroni

      5/2/25 8:00:00 AM ET
      $ECOR
      $NURO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • electroCore's Truvaga™ Now Works with the Apple Health app

      ROCKAWAY, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its flagship wellness product, Truvaga Plus, now works with the Apple® Health app. Truvaga Plus is a hand-held vagus nerve stimulator designed to elevate the day-to-day experience through quick and gentle activation of your vagus nerve. The product is designed to provide stress relief, improve sleep, enhance peace of mind and improve focus. Danielle Jones, Sr. Director of Direct-to-Consumer Marketing at electroCore, commented, "Using Truvaga Plus with the Apple Health app on the iPhone empowers you to better manage your hea

      5/1/25 8:00:00 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on electroCore with a new price target

      HC Wainwright & Co. reiterated coverage of electroCore with a rating of Buy and set a new price target of $2.75 from $3.00 previously

      1/19/22 6:31:24 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ladenburg Thalmann initiated coverage on electroCore with a new price target

      Ladenburg Thalmann initiated coverage of electroCore with a rating of Buy and set a new price target of $3.00

      7/27/21 7:13:01 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Maxim Group resumed coverage on electroCore with a new price target

      Maxim Group resumed coverage of electroCore with a rating of Buy and set a new price target of $3.00

      3/13/21 8:17:18 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gandolfo John P bought $9,018 worth of shares (1,800 units at $5.01), increasing direct ownership by 3% to 69,087 units (SEC Form 4)

      4 - electroCore, Inc. (0001560258) (Issuer)

      5/27/25 9:27:51 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Errico Thomas J. bought $47,735 worth of shares (10,000 units at $4.77), increasing direct ownership by 4% to 266,401 units (SEC Form 4)

      4 - electroCore, Inc. (0001560258) (Issuer)

      5/13/25 2:00:21 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Goldberger Daniel S bought $8,590 worth of shares (1,000 units at $8.59), increasing direct ownership by 0.35% to 290,565 units (SEC Form 4)

      4 - electroCore, Inc. (0001560258) (Issuer)

      3/18/25 10:52:56 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Gandolfo John P bought $9,018 worth of shares (1,800 units at $5.01), increasing direct ownership by 3% to 69,087 units (SEC Form 4)

      4 - electroCore, Inc. (0001560258) (Issuer)

      5/27/25 9:27:51 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Errico Thomas J. bought $47,735 worth of shares (10,000 units at $4.77), increasing direct ownership by 4% to 266,401 units (SEC Form 4)

      4 - electroCore, Inc. (0001560258) (Issuer)

      5/13/25 2:00:21 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Goldberger Daniel S bought $8,590 worth of shares (1,000 units at $8.59), increasing direct ownership by 0.35% to 290,565 units (SEC Form 4)

      4 - electroCore, Inc. (0001560258) (Issuer)

      3/18/25 10:52:56 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by electroCore Inc. (Amendment)

      SC 13D/A - electroCore, Inc. (0001560258) (Subject)

      6/7/24 4:33:08 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by electroCore Inc. (Amendment)

      SC 13G/A - electroCore, Inc. (0001560258) (Subject)

      2/14/24 3:15:55 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D filed by electroCore Inc.

      SC 13D - electroCore, Inc. (0001560258) (Subject)

      12/18/23 4:10:26 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Financials

    Live finance-specific insights

    See more
    • electroCore Announces First Quarter 2025 Financial Results

      First quarter 2025 net sales of $6.7 million, an increase of 23% over first quarter 2024 Closed the acquisition of NeuroMetrix, Inc. ("NeuroMetrix"); first quarter 2025 unaudited Quell net sales of approximately $170,000  Company to host a conference call and webcast today, May 7, 2025 at 4:30 PM EDT ROCKAWAY, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic technology company, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights Reported first quarter 2025 revenue of $6.7 million, a 23% increase over first quarter 2024Revenue excluding TAC-STIM totaled $

      5/7/25 4:05:00 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • electroCore Announces Full Year 2024 Financial Results

      Record full year 2024 net sales of $25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCoreTM in the United States Department of Veteran Affairs and United States Department of Defense (VA) and 174% increase in TruvagaTM sales Company to host a conference call and webcast today, March 12, 2025 at 5:30pm EDT ROCKAWAY, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a commercial-stage bioelectronic medicine Company and wellness company, today announced fourth quarter and full year 2024 financial results. Recent Highlights Reported record full year of 2024 revenue of $25.2 m

      3/12/25 4:05:00 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

      ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025. Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions. Conference Call & Webcast Details Date: Wednesday, March 12, 2025Time: 5:30 PM EDTRegistration: Click here to register to receive login credentials and dial-in details. About electroCore, Inc.electroCore, Inc. is a commercial-stage bioelectronic medicine a

      3/6/25 8:00:00 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Leadership Updates

    Live Leadership Updates

    See more
    • electroCore to Join Russell Microcap® Index

      ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the preliminary additions list for inclusion in the Russell Microcap® Index after its 2024 annual reconstitution. The newly reconstituted indexes will take effect after the market close on June 28, 2024, with the newly effective reconstituted family of indices beginning trading after the open of trading on July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on May 24, 2024. "We are pleased to have been selected to join the Russell Microcap® Index," said Brian Posner, Chief Finan

      6/11/24 8:00:00 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Firefly Neuroscience, an AI-Driven Brain Health Company, Names Brian S. Posner to its Board of Directors, Upon Closing of Its Merger Transaction with WaveDancer

      FAIRFAX, Va. and TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ("Firefly"), a pioneering artificial intelligence ("AI") company developing innovative neuroscientific solutions to improve outcomes for patients with mental illnesses and neurological disorders, today announced the appointment of Brian M. Posner to its Board of Directors upon closing of its planned merger with WaveDancer, Inc. ("WaveDancer") (NASDAQ:WAVD). Firefly has entered into a definitive agreement and plan of merger (as amended, the "Merger Agreement") with WaveDancer, which has been approved by the stockholders of both companies and both companies are working towards meeting the final closing cond

      5/29/24 9:00:00 AM ET
      $ECOR
      $WAVD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • electroCore Announces Changes to its Board of Directors

      ROCKAWAY, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Julie Bruzzone Goldstein and Tricia Wilber to the company's Board of Directors effective March 15, 2022. The Company also announced that effective March 4, 2022, Dr. Stephen Ondra is resigning from the Board to focus on his new role as Chief Medical Advisor at MITRE, and Michael Atieh will not be standing for re-election to the Board at the 2022 Annual General Meeting.   "Ms. Goldstein and Ms. Wilber are successful business leaders with proven track records, and I am pleased to welcome them to our Board," said Peter Cuneo

      3/9/22 11:30:00 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Stock Movement: Insider Purchase at electroCore Inc. on Jun 6

      **Analysis of Recent Insider Purchase at electroCore Inc.** An insider purchase was recently made at electroCore Inc. by Goldberger Daniel S on June 6, 2024. This transaction involved the purchase of $247,587 worth of shares, equating to 38,505 units at an average price of $6.43 per share. As a result of this purchase, Goldberger's direct ownership in the company increased by 18% to 249,565 units, as reported in the SEC Form 4 filing. Looking at the historical insider transactions at electroCore Inc., several interesting patterns emerge when analyzing the timing, price, volume, purchaser's role, and more. On August 8, 2023, Goldstein Julie Ann and Cuneo F Peter both filed SEC Form 4 report

      6/10/24 12:57:57 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care